Abstract
W hen choosing disease management programmes to fund, health maintenance organisations must consider both the needs of its membership and the realities of economic survival - what is good for patients is not necessarily good for the bottom-line. In the case of breast cancer, a programme encouraging the use of the new hormonal therapy drug tamoxifen would provide clear benefits for women since the agent has been shown to reduce the risk of breast cancer by 49%. But what about the cost of such a programme? Researchers at the 4th annual Disease Management Congress [ Boston, Massachusetts, US; October 1999 ] presented data examining the cost of breast cancer in two managed-care populations and the impact of a breast cancer risk management programme.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
